TRACON PHARMACEUTICALS INC's ticker is TCON and the CUSIP is 89237H209. A total of 22 filers reported holding TRACON PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31 | -34.0% | 176 | +8.0% | 0.00% | – |
| Q2 2023 | $47 | -88.9% | 163 | -27.2% | 0.00% | – |
| Q1 2023 | $423 | +31.0% | 224 | +3.2% | 0.00% | – |
| Q4 2022 | $323 | -67.7% | 217 | -76.2% | 0.00% | – |
| Q3 2022 | $1,000 | -50.0% | 910 | 0.0% | 0.00% | – |
| Q2 2022 | $2,000 | 0.0% | 910 | +1.6% | 0.00% | – |
| Q1 2022 | $2,000 | -33.3% | 896 | -32.6% | 0.00% | – |
| Q4 2021 | $3,000 | -40.0% | 1,330 | 0.0% | 0.00% | – |
| Q3 2021 | $5,000 | -91.2% | 1,330 | -84.8% | 0.00% | – |
| Q2 2021 | $57,000 | +35.7% | 8,759 | +74.4% | 0.00% | – |
| Q1 2021 | $42,000 | -51.2% | 5,022 | -31.5% | 0.00% | – |
| Q4 2020 | $86,000 | +514.3% | 7,329 | +166.1% | 0.00% | – |
| Q3 2020 | $14,000 | +366.7% | 2,754 | +53.2% | 0.00% | – |
| Q2 2020 | $3,000 | -82.4% | 1,798 | -82.1% | 0.00% | – |
| Q1 2020 | $17,000 | +183.3% | 10,062 | +275.9% | 0.00% | – |
| Q4 2019 | $6,000 | – | 2,677 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 4,125,322 | $8,251,000 | 3.72% |
| Ikarian Capital, LLC | 2,788,853 | $5,577,000 | 1.02% |
| Telemetry Investments, L.L.C. | 100,000 | $200,000 | 0.24% |
| ACT CAPITAL MANAGEMENT, LLC | 28,500 | $57,000 | 0.08% |
| JOHNSON & JOHNSON | 84,003 | $168,000 | 0.04% |
| NEA Management Company, LLC | 346,719 | $693,000 | 0.04% |
| X-Square Capital, LLC | 17,973 | $36,000 | 0.02% |
| BOOTHBAY FUND MANAGEMENT, LLC | 268,301 | $537,000 | 0.01% |
| LINDEN ADVISORS LP | 454,916 | $910,000 | 0.01% |
| DOWLING & YAHNKE LLC | 47,455 | $95,000 | 0.00% |